Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Open Access
- 12 April 2024
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (4) , 494
Abstract
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.Keywords
This publication has 120 references indexed in Scilit:
- 1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutationsAnnals of Oncology, 2023
- Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignanciesHematological Oncology, 2023
- Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast CancerAngewandte Chemie International Edition, 2021
- Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challengesBioorganic & Medicinal Chemistry Letters, 2019
- Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 spaceCurrent Opinion in Chemical Biology, 2018
- Plasma Protein Binding of Challenging CompoundsJournal of Pharmaceutical Sciences, 2015
- Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1αAngewandte Chemie International Edition, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Intestinal lymphatic transport for drug deliveryAdvanced Drug Delivery Reviews, 2011
- Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein BindingJournal of Pharmaceutical Sciences, 2008